David L. Shelton

10.3k citations

62 papers · 7.6k indexed · 3 hit papers · h-index 36

Cellular and Molecular Neuroscience top 0.2%
Physiology top 0.5%
Molecular Biology top 5%
Developmental Neuroscience top 0.2%
Pharmacology top 1%

Co-authors: Louis F. Reichardt Stephen B. McMahon David Bennett Heidi Phillips John V. Priestley Arnon Rosenthal Martin Koltzenburg Hyejin Kang
Topics: Nerve injury and regeneration (26 papers)Pain Mechanisms and Treatments (14 papers)Neuropeptides and Animal Physiology (13 papers)
Cited by: Developmental Neuroscience Cellular and Molecular Neuroscience Physiology
Journals: New England Journal of Medicine Cell Proceedings of the National Academy of Sciences
Partner nations: United States United Kingdom Germany

In The Last Decade

David L. Shelton

62 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons

1994 874 citations Stephen B. McMahon, David L. Shelton et al. profile →
FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family

2000 551 citations David L. Shelton et al. profile →
Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee

2010 499 citations David L. Shelton et al. profile →

Peers

Countries citing papers authored by David L. Shelton

Since Specialization

Citations

This map shows the geographic impact of David L. Shelton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Shelton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Shelton more than expected).

Fields of papers citing papers by David L. Shelton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Shelton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Shelton. The network helps show where David L. Shelton may publish in the future.

Co-authorship network of co-authors of David L. Shelton

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Shelton. A scholar is included among the top collaborators of David L. Shelton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Shelton. David L. Shelton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates 2019 ·Scientific Reports ·(unknown),(unknown),(unknown),Wei-Hsien Ho,Kathy Delaria,(unknown),(unknown),(unknown),(unknown),Eileen Blasi,Bernard S. Buetow,Thomas-Toan Tran,Kevin C. Lindquist,Magdalena Dorywalska,Arvind Rajpal,David L. Shelton,Pavel Strop,Shu‐Hui Liu	14
2	The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies 2017 ·Cardiovascular Therapeutics ·Barry Gumbiner,Tenshang Joh,Liang Hong,Hong Wan,Matteo Levisetti,(unknown),David L. Shelton,(unknown),(unknown),Jaume Pons,Charles M. Baum,Pamela D. Garzone	14
3	Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates 2017 ·Bioconjugate Chemistry ·Rachel M. DeVay,Kathy Delaria,Guoyun Zhu,(unknown),Davide Foletti,Janette Sutton,Gary L. Bolton,Russell G. Dushin,Christine Bee,Jaume Pons,Arvind Rajpal,Liang Hong,David L. Shelton,Shu‐Hui Liu,Pavel Strop	42
4	Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design 2016 ·Molecular Cancer Therapeutics ·Magdalena Dorywalska,Russell G. Dushin,Ludivine Moine,Santiago Farias,Dahui Zhou,Thayalan Navaratnam,Victor Lui,Adela Hasa-Moreno,Meritxell Galindo Casas,Thomas-Toan Tran,Kathy Delaria,Shu‐Hui Liu,Davide Foletti,Christopher J. O’Donnell,Jaume Pons,David L. Shelton,Arvind Rajpal,Pavel Strop	162
5	Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model 2016 ·Annals of the Rheumatic Diseases ·Timothy P. LaBranche,Alison M. Bendele,(unknown),Kathryn E. Gropp,Susan Hurst,Cedo M. Bagi,(unknown),(unknown),David L. Shelton,Mark Zorbas	44
6	Modulation of P2X3 and P2X2/3 Receptors by Monoclonal Antibodies 2016 ·Journal of Biological Chemistry ·Anatoly Shcherbatko,Davide Foletti,Kris Poulsen,Pavel Strop,Guoyun Zhu,Adela Hasa-Moreno,Jody Melton Witt,(unknown),Stellanie Krimm,(unknown),Jessica Yu,Colleen Brown,John K. Lee,Robert M. Stroud,Arvind Rajpal,David L. Shelton	29
7	Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function 2015 ·PLoS ONE ·Rachel M. DeVay,(unknown),David L. Shelton,Liang Hong	14
8	Precise and Efficient Antibody Epitope Determination through Library Design, Yeast Display and Next-Generation Sequencing 2014 ·Journal of Molecular Biology ·Thomas Van Blarcom,Andrea Rossi,Davide Foletti,Purnima Sundar,Steven J. Pitts,Christine Bee,Jody Melton Witt,Zea Melton,Adela Hasa-Moreno,Lee Shaughnessy,Dilduz Telman,Lora Zhao,Wai Ling Cheung‐Lee,Jan Berka,Wenwu Zhai,Pavel Strop,Javier Chaparro‐Riggers,David L. Shelton,Jaume Pons,Arvind Rajpal	50
9	Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis) 2014 ·Reproductive Toxicology ·Christopher Bowman,Mark G. Evans,(unknown),Satoru Oneda,Mark T. Butt,Susan Hurst,(unknown),David L. Shelton,Cris Kamperschroer,Mark Zorbas	12
10	Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2) 2013 ·Journal of Biological Chemistry ·Rachel M. DeVay,David L. Shelton,Liang Hong	51
11	Sciatic nerve regeneration is not inhibited by anti-NGF antibody treatment in the adult rat 2013 ·Neuroscience ·Karen L. Lankford,Edgardo J. Arroyo,Chang‐Ning Liu,(unknown),Mark Zorbas,David L. Shelton,Mark G. Evans,Susan Hurst,Jeffery D. Kocsis	8
12	Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Liang Hong,Javier Chaparro‐Riggers,Pavel Strop,Tao Geng,Janette Sutton,Daniel Tsai,Lanfang Bai,Yasmina Abdiche,Jeanette Dilley,Jessica A. Yu,Si Wu,Sherman M. Chin,(unknown),Andrea Rossi,John Lin,Arvind Rajpal,Jaume Pons,David L. Shelton	90
13	CGRP function‐blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat 2008 ·British Journal of Pharmacology ·James R. Zeller,Kris Poulsen,Janette Sutton,Yasmina Abdiche,Scott R. Collier,Rajiv Chopra,Carlos García,Jaime Pons,Arnon Rosenthal,David L. Shelton	73
14	Artemin has potent neurotrophic actions on injured C‐fibres 2006 ·Journal of the Peripheral Nervous System ·David Bennett,(unknown),Gregory J. Michael,Reena J. Popat,Marzia Malcangio,Sharon Averill,Kris Poulsen,John V. Priestley,David L. Shelton,Stephen B. McMahon	37
15	Novel class of pain drugs based on antagonism of NGF 2005 ·Trends in Pharmacological Sciences ·Franz Hefti,Arnon Rosenthal,Patricia A. Walicke,Séan Wyatt,(unknown),David L. Shelton,Alun M. Davies	287
16	Antibody Binding Regions on Human Nerve Growth Factor Identified by Homolog- and Alanine-Scanning Mutagenesis 2000 ·Hybridoma ·Jo-Anne Hongo,Gary R. Laramee,Roman Urfer,David L. Shelton,(unknown),M D Sadick,(unknown),Herman Chu,John Winslow	28
17	Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat 1998 ·European Journal of Neuroscience ·David Bennett,Martin Koltzenburg,John V. Priestley,David L. Shelton,Stephen B. McMahon	102
18	The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule 1995 ·Nature Medicine ·Stephen B. McMahon,David Bennett,John V. Priestley,David L. Shelton	358
19	A novel group of nerve growth factor receptor-immunoreactive neurons in the ventral horn of the lumbar spinal cord 1991 ·Brain Research ·Vassilis E. Koliatsos,David L. Shelton,William C. Mobley,Donald L. Price	29
20	Studies on the expression of the beta nerve growth factor (NGF) gene in the central nervous system: level and regional distribution of NGF mRNA suggest that NGF functions as a trophic factor for several distinct populations of neurons. 1986 ·Proceedings of the National Academy of Sciences ·David L. Shelton,Louis F. Reichardt	453

About David L. Shelton

David L. Shelton is a scholar working on Developmental Neuroscience, Cellular and Molecular Neuroscience and Physiology, having authored 62 papers that have together received 7.6k indexed citations. Recurring topics across this work include Nerve injury and regeneration (26 papers), Pain Mechanisms and Treatments (14 papers) and Neuropeptides and Animal Physiology (13 papers). The work is most often cited by research in Developmental Neuroscience (1.3k citations), Cellular and Molecular Neuroscience (4.0k citations) and Physiology (2.3k citations). David L. Shelton has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Louis F. Reichardt, Stephen B. McMahon, David Bennett, Heidi Phillips, John V. Priestley, Arnon Rosenthal, Martin Koltzenburg, Hyejin Kang, Erin M. Schuman and Carla J. Shatz. Their work appears in journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact